Hvilken er prisen på GeneOne Life Science, Inc. (011000)

Prisen på GeneOne Life Science, Inc. (011000) er $1.85

Hva er markedsverdien på GeneOne Life Science, Inc. (011000)

Markedsverdien på GeneOne Life Science, Inc. (011000) er $32.07M

GeneOne Life Science, Inc. (011000) Utbytte

GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul, South Korea, was founded in 1976. The company focuses on the innovation and manufacturing of gene-based biomedical products. Its developmental pipeline features several candidates: GLS-1027 is in Phase I for nephropathy and inflammatory conditions, and also in Phase II trials for COVID-19. Similarly, GLS-1200 is being tested in Phase II for both Rhinosinusitis and COVID-19. Other compounds under development include GLS-3000 and GLS-5310 for SARS-CoV-2, GLS-5100 targeting VZV-Shingles, and GLS-5140 for SFTS. The company is also advancing GLS-5300 in Phase II for MERS, GLS-5700 in Phase I for Zika, and GLS-6150 in Phase I for hepatitis C, alongside GLS-6100 which is in a pre-clinical stage for hepatitis C. Additionally, through its subsidiary VGXI, Inc., GeneOne Life Science offers contract manufacturing services for nucleic acid-based products, specifically DNA plasmids and mRNA, under cGMP standards. The company adopted its current name in April 2014, having previously been known as VGX International Inc.

År	Utbytte (justert for aksjesplitt)	Endre
Ikke nok data for de angitte datoene.

År

Utbytte (justert for aksjesplitt)

Endre

Ikke nok data for de angitte datoene.

År	Utbytte	Endre
Ikke nok data for de angitte datoene.

År

Utbytte

Endre

Ikke nok data for de angitte datoene.

Selskap	Antall utbyttebetalinger	Land
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Moderna, Inc. MRNA.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
CSL Limited CSL.AX	64.00%	AU
Lonza Group AG LONN.SW	0.00%	CH

Selskap

Antall utbyttebetalinger

Land